When India’s Prime Minister Narendra Modi spoke about the dangers of rising obesity in his public addresses over the past few years, the message was framed as a lifestyle warning. He urged citizens to reduce cooking oil consumption, adopt healthier diets and exercise more. His comments reflected a growing concern among doctors and policymakers that India was facing a silent but rapidly expanding metabolic health crisis.
Those concerns are backed by global data. According to the World Obesity Atlas 2026 published by the World Obesity Federation, India now ranks second globally in the number of children living with obesity. The report warns that the country could see tens of millions of children and adolescents affected by obesity in the coming years if current trends continue.
At the same time that obesity is moving to the centre of India’s public health debate, a powerful new class of drugs designed to treat the condition has begun entering the market.
The arrival of these medicines has opened a new front in the fight against obesity. It has also sparked a deeper conversation about how pharmaceutical companies shape health narratives.
A Blockbuster Drug Arrives
In 2025, the American pharmaceutical giant Eli Lilly launched its much anticipated drug Mounjaro in India after receiving regulatory approval. Originally developed as a treatment for type 2 diabetes, the drug quickly gained global attention for its ability to produce significant weight loss by regulating appetite and blood sugar.
The drug belongs to a class known as GLP 1 receptor agonists, medicines that mimic hormones involved in metabolism and hunger signals. In clinical trials, patients taking the therapy experienced substantial reductions in body weight.
For people living with severe obesity or diabetes, such treatments could offer important medical benefits. But the speed with which Mounjaro gained traction in India surprised many industry observers.
Within months of its launch, the drug had crossed major sales milestones and rapidly climbed the rankings of India’s top selling medicines by value.
The commercial success reflected the enormous market potential of obesity treatments.
Awareness Campaign That Sparked Debate
India prohibits direct advertising of prescription medicines to the public under the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954. That means companies cannot openly promote drugs like Mounjaro through conventional consumer advertising.
Yet pharmaceutical marketing rarely stops at regulatory barriers.
Instead of advertising the drug directly, Eli Lilly launched a nationwide obesity awareness campaign that framed obesity as a chronic medical disease rather than a lifestyle issue. The campaign emphasised that weight gain is influenced by biology and metabolism and encouraged people to consult doctors about treatment.
On the surface, such campaigns appear to be public health education. In practice, critics say they often function as indirect marketing strategies.
By reshaping how obesity is understood, awareness campaigns can expand the potential market for pharmaceutical treatment without explicitly naming a specific drug.
Health policy experts note that this strategy is widely used by pharmaceutical companies in countries where direct advertising of prescription medicines is restricted.
Global Strategy With High Stakes
The obesity drug boom is not limited to India. Globally, pharmaceutical companies are racing to dominate what analysts believe could become one of the most valuable segments of the healthcare industry.
Another widely discussed drug is Ozempic developed by Novo Nordisk. The medicine gained international attention after celebrities and influencers began speaking about dramatic weight loss associated with its use.
The surge in demand created what many observers began calling the “Ozempic economy”, a phenomenon in which clinics, wellness companies and online prescription services built entire businesses around weight loss injections.
Novo Nordisk’s current chief executive Maziar Mike Doustdar has continued expanding the company’s obesity drug portfolio globally, while the earlier leadership of Lars Fruergaard Jørgensen played a major role in positioning obesity as a chronic disease requiring long term medical treatment.
The financial stakes are enormous. Analysts estimate the global obesity drug market could exceed 100 billion dollars annually within the next decade.
Social Media Effect & Rising Misuse
As these medicines gained visibility, doctors began noticing a new trend. Increasing numbers of people were seeking weight loss injections for cosmetic reasons rather than medical necessity.
In several countries, patients who were not clinically obese began requesting prescriptions after seeing celebrities discuss the drugs online.
Doctors warn that this trend carries risks. These medicines were developed for specific metabolic conditions and require medical supervision. Side effects can include gastrointestinal complications and other metabolic disturbances.
Public health experts worry that social media hype may be pushing the drugs beyond their intended medical use. Many social media users and health commentators have also voiced scepticism about the expanding obesity drug market.
Some critics argue that multinational food and beverage companies helped accelerate unhealthy eating habits in developing countries by aggressively marketing sugary drinks and ultra processed foods. Now, they say, the same global corporate ecosystem appears to be profiting from pharmaceutical treatments designed to address the very health problems linked to those diets.
Indian Pharma Joins The Race
The obesity drug boom is also attracting India’s own pharmaceutical companies.
Major firms including Dr. Reddy’s Laboratories and other domestic manufacturers are exploring ways to enter the obesity treatment market as patents for some global drugs begin to expire in the coming years.
This could eventually lead to lower cost alternatives, making the therapies more accessible.
At the same time, it may also intensify competition in a market already attracting enormous global investment.
The Ethical Question
For doctors and public health experts, the debate is not about rejecting medical innovation. Many acknowledge that obesity drugs can help patients who struggle with severe metabolic disease.
The concern lies in the broader narrative around obesity.
For decades, researchers have emphasised that obesity is shaped by structural factors including food systems, urban planning, economic inequality and lifestyle changes. Addressing these drivers requires policy reforms that go far beyond medication.
When pharmaceutical solutions dominate public conversation, there is a risk that deeper causes receive less attention.
There is also the issue of affordability. Many of these drugs cost thousands of rupees per month, placing them beyond the reach of much of the population.
Turning Point In The Obesity Debate
India’s obesity crisis demands urgent action. Millions of people face rising risks of diabetes, heart disease and other chronic conditions linked to excess weight.
Medical innovation may offer new tools to address these challenges. But the growing influence of pharmaceutical companies in shaping the obesity narrative deserves careful scrutiny.
The arrival of blockbuster weight loss drugs has created enormous commercial opportunity. It has also raised fundamental questions about how health problems are framed, marketed and treated.
The future of obesity treatment in India will likely involve a combination of medical therapy, lifestyle change and public health policy.
The challenge will be ensuring that the conversation remains centred on long term health rather than the rapid growth of a lucrative global drug market.
The Logical Indian’s Perspective
India’s rising obesity rates deserve urgent attention, but the response must remain rooted in ethical healthcare and public wellbeing. Medicines can help patients who need them, yet public health solutions must go beyond pharmaceutical fixes.
Transparent marketing, responsible prescriptions, and prevention through healthier food systems and lifestyles are essential so that innovation supports people’s health without deepening inequality or commercialising illness.
